GPBAR1 and Hepatic fibrosis: At molecular level, we found that, while treating CCl4 mice with BAR501, had no effect on TGFβ1, collagen α1 and αSMA (i.e. on tissue markers of liver fibrosis), the GPBAR1 agonist effectively increased the expression of CSE without modulating the expression of eNOS and iNOS genes.